Innoviva (INVA) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.60% |
| Sep 30, 2025 | 40.10% |
| Jun 30, 2025 | 45.22% |
| Mar 31, 2025 | 37.62% |
| Sep 30, 2024 | 26.80% |
| Jun 30, 2024 | 28.22% |
| Mar 31, 2024 | 19.18% |
| Sep 30, 2023 | 55.90% |
| Jun 30, 2023 | 31.28% |
| Mar 31, 2023 | -5.93% |
| Sep 30, 2022 | 8.50% |
| Jun 30, 2022 | -11.07% |
| Mar 31, 2022 | -17.57% |
| Sep 30, 2021 | -20.60% |
| Jun 30, 2021 | -30.22% |
| Mar 31, 2021 | -24.71% |
| Dec 31, 2020 | -22.99% |
| Sep 30, 2020 | -21.38% |
| Jun 30, 2020 | -27.11% |
| Mar 31, 2020 | -25.79% |
| Dec 31, 2019 | -18.74% |
| Sep 30, 2019 | -36.49% |
| Jun 30, 2019 | -42.81% |
| Mar 31, 2019 | -46.29% |
| Dec 31, 2018 | -39.47% |
| Sep 30, 2018 | -15.22% |
| Jun 30, 2018 | -16.13% |
| Mar 31, 2018 | -18.67% |
| Dec 31, 2017 | -15.81% |
| Sep 30, 2017 | -15.77% |
| Jun 30, 2017 | -16.50% |
| Mar 31, 2017 | -16.66% |
| Dec 31, 2016 | -21.31% |
| Sep 30, 2016 | -24.25% |
| Jun 30, 2016 | -14.66% |
| Mar 31, 2016 | -19.58% |
| Dec 31, 2015 | -18.87% |
| Sep 30, 2015 | -20.06% |